{"entity":{"id":"nct05473624","kind":"trial","name":"Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT05473624 as recruiting, last updated 2025-04-15. Enrolment is 153 planned participants, an estimate. Interventions: HRS-1167. Primary measures include Dose-limiting toxicity (DLT) of HRS-1167; Maximum tolerated dose (MTD) of HRS-1167. No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT05473624","url":"https://clinicaltrials.gov/study/NCT05473624"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["parp"],"drugs":["hrs-1167"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05473624","phase":"1","setting":"A Phase I, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","started":"2022-08-23","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05473624/","neighbours":{"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"hrs-1167","kind":"drug","name":"HRS-1167","route":"/drugs/hrs-1167/"}]}}